GlassScriptPhysician profile
Mckenzie Baker
NPI 1801305859
$1,967.43
in general payments reported to CMS, 2019-2025
18 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.10 · 2022: $32.63 · 2023: $182 · 2024: $508 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Travel and Lodging: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.05 |
| Travel and Lodging | $369.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $545.31 | 2025 | Minimed 780g |
| Novo Nordisk INC | $308.33 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $296.37 | 2024-2025 | |
| Beta Bionics, INC. | $224.85 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $158.78 | 2025 | Twiist |
| Abbott Laboratories | $96.43 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $47.78 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2021 | |
| Lilly USA, LLC | $36.27 | 2024 | Zepbound, Mounjaro, Jardiance |
| Ascensia Diabetes Care US INC. | $34.90 | 2025 | |
| Xeris Pharmaceuticals, INC. | $34.39 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $31.13 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $27.84 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.63 | 2025 | Strensiq |
| Amryt Pharma Holdings LTD | $17.18 | 2023 | Mycapssa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $16.33 | 2025 | Azmiro |
| Tandem Diabetes Care, INC. | $14.67 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $14.14 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.